About the Authors

Lawrence J. Druhan

Affiliation The Department of Hematologic Oncology, The Levine Cancer Institute, Carolinas HealthCare System, Charlotte, North Carolina, United States of America

Amanda Lance

Affiliation The Department of Hematologic Oncology, The Levine Cancer Institute, Carolinas HealthCare System, Charlotte, North Carolina, United States of America

Shimena Li

Affiliation The University of North Carolina School of Medicine, Chapel Hill, North Carolina, United States of America

Andrea E. Price

Affiliation The Department of Hematologic Oncology, The Levine Cancer Institute, Carolinas HealthCare System, Charlotte, North Carolina, United States of America

Jacob T. Emerson

Affiliation The Department of Hematologic Oncology, The Levine Cancer Institute, Carolinas HealthCare System, Charlotte, North Carolina, United States of America

Sarah A. Baxter

Affiliation The Department of Hematologic Oncology, The Levine Cancer Institute, Carolinas HealthCare System, Charlotte, North Carolina, United States of America

Jonathan M. Gerber

Affiliation The Department of Hematologic Oncology, The Levine Cancer Institute, Carolinas HealthCare System, Charlotte, North Carolina, United States of America

Belinda R. Avalos

belinda.avalos@carolinashealthcare.org

Affiliation The Department of Hematologic Oncology, The Levine Cancer Institute, Carolinas HealthCare System, Charlotte, North Carolina, United States of America

Competing Interests

The authors have declared that no competing interests exist.

Author Contributions

Conceptualization: BRA LJD. Formal analysis: LJD AL. Funding acquisition: BRA LJD SL. Investigation: SL AL AEP JTE SAB. Methodology: BRA LJD AEP. Project administration: BRA LJD. Resources: BRA. Supervision: BRA LJD. Validation: LJD AL AEP. Visualization: LJD SL AL AEP. Writing – original draft: BRA LJD. Writing – review & editing: BRA LJD JMG.